Paradoxically however, high levels of TGFβ are often detected in advanced human breast cancer, and many preclinical studies have demonstrated that TGFβ can promote metastasis in late-stage disease, through direct effects on the tumor cell such as enhanced motility, invasion, and survival, as well as through effects on the tumor stroma, such as regulation of extracellular matrix composition, stimulation of angiogenesis and suppression of immunosurveillance (reviewed in [5-7]). Here, TGFB1 is linked to breast cancer.